{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T09:06:45Z","timestamp":1726304805385},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12325-022-02250-x","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T11:21:14Z","timestamp":1662117674000},"page":"5072-5086","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Farah","family":"Jivraj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Reedie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Strzok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Rock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"issue":"1","key":"2250_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00415-017-8676-8","volume":"265","author":"D Conradsson","year":"2018","unstructured":"Conradsson D, et al. Changes in disability in people with multiple sclerosis: a 10-year prospective study. J Neurol. 2018;265(1):119\u201326.","journal-title":"J Neurol"},{"issue":"1","key":"2250_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"2250_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"issue":"2","key":"2250_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018;24(2):96\u2013120.","journal-title":"Mult Scler J"},{"issue":"2","key":"2250_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1017\/S0317167100053804","volume":"31","author":"MS Freedman","year":"2004","unstructured":"Freedman MS, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci. 2004;31(2):157\u201368.","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"2250_CR6","first-page":"670","volume":"25","author":"LM Metz","year":"2019","unstructured":"Metz LM. Clinically isolated syndrome and early relapsing multiple sclerosis. Continuum. 2019;25(3):670\u201388.","journal-title":"Continuum"},{"issue":"10","key":"2250_CR7","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1093\/brain\/awaa251","volume":"143","author":"MP Amato","year":"2020","unstructured":"Amato MP, et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain. 2020;143(10):3013\u201324.","journal-title":"Brain"},{"key":"2250_CR8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3389\/fneur.2018.01150","volume":"9","author":"SB Claflin","year":"2019","unstructured":"Claflin SB, Broadley S, Taylor BV. The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses. Front Neurol. 2019;9:1150.","journal-title":"Front Neurol"},{"issue":"12","key":"2250_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144538","volume":"10","author":"G Tsivgoulis","year":"2015","unstructured":"Tsivgoulis G, et al. The effect of disease modifying therapies on disease progression in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. PLoS ONE. 2015;10(12): e0144538.","journal-title":"PLoS ONE"},{"key":"2250_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","volume":"22","author":"SL Cohan","year":"2018","unstructured":"Cohan SL, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27\u201334.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"2250_CR11","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.clinthera.2018.10.011","volume":"40","author":"K Kresa-Reahl","year":"2018","unstructured":"Kresa-Reahl K, et al. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a Prospective Observational Study. Clin Ther. 2018;40(12):2077\u201387.","journal-title":"Clin Ther"},{"issue":"4","key":"2250_CR12","first-page":"105","volume":"11","author":"AR Zadeh","year":"2019","unstructured":"Zadeh AR, et al. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. Int J Physiol Pathophysiol Pharmacol. 2019;11(4):105.","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"2250_CR13","doi-asserted-by":"publisher","first-page":"175628642199399","DOI":"10.1177\/1756286421993999","volume":"14","author":"A Wundes","year":"2021","unstructured":"Wundes A, et al. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Ther Adv Neurol Disord. 2021;14:1756286421993999.","journal-title":"Ther Adv Neurol Disord"},{"key":"2250_CR14","unstructured":"Wundes, A., et al. Improved GI Tolerability With Diroximel Fumarate Is Associated With Clinically Meaningful Benefits on Quality of Life Compared With Dimethyl Fumarate in EVOLVE-MS-2. In: 8th Joint ACTRIMS-ECTRIMS Meeting. 2020. Multiple Scler J. 2020;26(3_suppl):118\u2013659."},{"issue":"2","key":"2250_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185\u201396.","journal-title":"CNS Drugs"},{"key":"2250_CR16","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2018; Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Patient-Focused-Drug-Development---Collecting-Comprehensive-and-Representative-Input.pdf. Accessed 22 Jan 2022."},{"key":"2250_CR17","unstructured":"US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. 2019. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 22 Jan 2022."},{"key":"2250_CR18","unstructured":"US Food and Drug Administration. Patient focused drug development: select, develop, or modify fit-for-purpose clinical outcomes assessments. 2018. https:\/\/www.fda.gov\/media\/116277\/download. Accessed 22 Jan 2022."},{"key":"2250_CR19","unstructured":"US Food and Drug Administration. Patient focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. 2019. https:\/\/www.fda.gov\/media\/132505\/download. Accessed 22 Jan 2022."},{"key":"2250_CR20","unstructured":"Institut national d'exellence en sante et services sociaux, Evaluation of drugs for listing purposes: a change of approach, INESSS, Editor. 2018: Quebec, Canada."},{"key":"2250_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95: 103208.","journal-title":"J Biomed Inf"},{"issue":"2","key":"2250_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"},{"issue":"2","key":"2250_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u201390.","journal-title":"Qual Res Psychol"},{"key":"2250_CR24","volume-title":"Research methods in health: investigating health and health services","author":"A Bowling","year":"2009","unstructured":"Bowling A. Research methods in health: investigating health and health services. 3rd ed. Maidenhead: Open University Press; 2009.","edition":"3"},{"key":"2250_CR25","doi-asserted-by":"publisher","DOI":"10.4324\/9780203413081","volume-title":"Analyzing qualitative data","author":"A Bryman","year":"2002","unstructured":"Bryman A, Burgess B. Analyzing qualitative data. New York: Routledge; 2002."},{"issue":"2","key":"2250_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237\u201346.","journal-title":"Am J Eval"},{"key":"2250_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/104973239500500201","volume-title":"The significance of saturation","author":"JM Morse","year":"1995","unstructured":"Morse JM. The significance of saturation. Thousand Oaks: Sage publications Sage CA; 1995."},{"key":"2250_CR28","volume-title":"Basics of qualitative research: Grunded theory procedures and techniques","author":"ACT Strauss","year":"1990","unstructured":"Strauss ACT. Basics of qualitative research: Grunded theory procedures and techniques. London: Sage; 1990."},{"issue":"5","key":"2250_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1177\/1359105306066643","volume":"11","author":"J Meyrick","year":"2006","unstructured":"Meyrick J. What is good qualitative research? A first step towards a comprehensive approach to judging rigour\/quality. J Health Psychol. 2006;11(5):799\u2013808.","journal-title":"J Health Psychol"},{"issue":"2","key":"2250_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1212\/WNL.45.2.251","volume":"45","author":"MJ Hohol","year":"1995","unstructured":"Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45(2):251\u20135.","journal-title":"Neurology"},{"key":"2250_CR31","unstructured":"US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 22 Jan 2022."},{"key":"2250_CR32","unstructured":"ERT and Endpoint Outcomes, GI tolerability instrument development in fumarate-based treatments for multiple sclerosis. 2018."},{"issue":"1","key":"2250_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-020-01830-0","volume":"20","author":"JA Nicholas","year":"2020","unstructured":"Nicholas JA, et al. Real-world adherence to, and persistence with, once-and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurol. 2020;20(1):1\u201315.","journal-title":"BMC Neurol"},{"issue":"1","key":"2250_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1186\/s12913-021-07012-z","volume":"21","author":"A Sippel","year":"2021","unstructured":"Sippel A, et al. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study. BMC Health Serv Res. 2021;21(1):1141.","journal-title":"BMC Health Serv Res"},{"key":"2250_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102507","volume":"46","author":"A Manzano","year":"2020","unstructured":"Manzano A, et al. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;46: 102507.","journal-title":"Mult Scler Relat Disord"},{"key":"2250_CR36","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/PPA.S142373","volume":"11","author":"G Lee Mortensen","year":"2011","unstructured":"Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. Patient Prefer Adherence. 2011;11:1789\u201396.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"2250_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1756285616648060","volume":"9","author":"LD Lynd","year":"2016","unstructured":"Lynd LD, et al. Quantitative analysis of multiple sclerosis patients\u2019 preferences for drug treatment: a best-worst scaling study. Ther Adv Neurol Disord. 2016;9(4):287\u201396.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"2250_CR38","doi-asserted-by":"publisher","first-page":"1648946","DOI":"10.1080\/17482631.2019.1648946","volume":"14","author":"E Van Reenen","year":"2019","unstructured":"Van Reenen E, et al. Fear, fight, familiarize: the experiences of people living with relapsing-remitting multiple sclerosis and taking oral medication. Int J Qual Stud Health Well-Being. 2019;14(1):1648946.","journal-title":"Int J Qual Stud Health Well-Being"},{"issue":"1","key":"2250_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/hex.12599","volume":"21","author":"IEH Kremer","year":"2018","unstructured":"Kremer IEH, et al. Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: a best-worst scaling. Health Expect. 2018;21(1):171\u201380.","journal-title":"Health Expect"},{"issue":"2","key":"2250_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/0272989X19897944","volume":"40","author":"MF Jonker","year":"2020","unstructured":"Jonker MF, et al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. Med Decis Making. 2020;40(2):198\u2013211.","journal-title":"Med Decis Making"},{"issue":"1","key":"2250_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12883-019-1382-7","volume":"19","author":"N Bansback","year":"2019","unstructured":"Bansback N, et al. Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients. BMC Neurol. 2019;19(1):173.","journal-title":"BMC Neurol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02250-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02250-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02250-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T15:48:09Z","timestamp":1664552889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02250-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02250-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}